U.S. Patent and Trademark Office, U.S. DEPARTMENT
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless of contains a valid OMI

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10597952			
iling Date					
irst Named Inventor Noel		Sidney Davidson Wood			
Art Unit					
xaminer Name					
Marray Danket Numb		EARY 0404 DUCA			

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	ate	of cited Document		Releva	Columns,Lines where int Passages or Relev s Appear	
	1	5918907		1999-07	-06	Cheng-Cheng Ho				
	2	5765799		1998-06	i-16	Barbara Weber				
	3 3991967 1976-11-16 Harry Sack									
If you wish to add additional U.S. Patent citation information please click the Add button. Add										
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Patentee or Applicant of cited Document		Releva	Columns,Lines where int Passages or Relev s Appear	
	1	20040173725		2004-09	1-09	Antonio Rodriguez Villaneuva				
If you wis	h to a	dd additional U.S. Publi:	shed Ap	plication	citatio	n information p	olease click the Ad	d button	Add	
	FOREIGN PATENT DOCUMENTS Remove									
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²			Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	Ts
	1	2229887	CA			1998-08-19	Brayford Myrna (C/	w		

U.S. PATENTS

Application Number 10597952 Filing Date Fi

	2	2228406	GB		1990-08-29	Thomas Gervase McKeown		
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner linitials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposisum, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Τs		
1								
If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE								
Examiner	Signa	ture				Date Considered		
*EYAMIN	*EVAMINED: Initial if reference considered whether or not citation is in conformance with MDED COO. Draw line through a							

See Kind Codes of USPTO Patient Documents at your USPTO DOLL or MEPP 0910.4. Tester office make assed for document, by the he-letter code (WIPD Standard ST3.). "Polyagenees getered conversels, we included not be parent for seriory of the dispersor parent polyagenees greated conversels, we included on the document of the dispersor parent polyagenees greated as the document of the dispersor parent polyagenees greated as the document of the dispersor parent greated as the document of the dispersor parent greated as the document of the dispersor parent greated as the dispersor parent greated as the dispersor parent greated as the dispersor parent greated gre

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10597952
Filing Date		90-
First Named Inventor	Noel:	Sidney Davidson Wood
Art Unit		
Examiner Name		
Attorney Docket Number		EASY 0101 PUSA

CERTIFICATION STATEMENT

Please see 37	7 CFR 1.97	and 1.98 to	make the	appropriate	selection(s):	
---------------	------------	-------------	----------	-------------	---------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/John E. Nemazi/	Date (YYYY-MM-DD)	2007-02-23
Name/Print	John F. Nemazi	Registration Number	30.876

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiler. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.